GB9828640D0 - Novel method and compounds - Google Patents

Novel method and compounds

Info

Publication number
GB9828640D0
GB9828640D0 GBGB9828640.4A GB9828640A GB9828640D0 GB 9828640 D0 GB9828640 D0 GB 9828640D0 GB 9828640 A GB9828640 A GB 9828640A GB 9828640 D0 GB9828640 D0 GB 9828640D0
Authority
GB
United Kingdom
Prior art keywords
compounds
novel method
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9828640.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9828640.4A priority Critical patent/GB9828640D0/en
Publication of GB9828640D0 publication Critical patent/GB9828640D0/en
Priority to PCT/GB1999/004374 priority patent/WO2000038675A1/en
Priority to EP99962419A priority patent/EP1140070A1/en
Priority to AU18777/00A priority patent/AU1877700A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
GBGB9828640.4A 1998-12-23 1998-12-23 Novel method and compounds Ceased GB9828640D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB9828640.4A GB9828640D0 (en) 1998-12-23 1998-12-23 Novel method and compounds
PCT/GB1999/004374 WO2000038675A1 (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3
EP99962419A EP1140070A1 (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3
AU18777/00A AU1877700A (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828640.4A GB9828640D0 (en) 1998-12-23 1998-12-23 Novel method and compounds

Publications (1)

Publication Number Publication Date
GB9828640D0 true GB9828640D0 (en) 1999-02-17

Family

ID=10845024

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9828640.4A Ceased GB9828640D0 (en) 1998-12-23 1998-12-23 Novel method and compounds

Country Status (4)

Country Link
EP (1) EP1140070A1 (en)
AU (1) AU1877700A (en)
GB (1) GB9828640D0 (en)
WO (1) WO2000038675A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res Drugs inhibiting cell death
EP1244461A2 (en) * 1999-12-23 2002-10-02 The Ontario Cancer Institute INHIBITION OF GSK-3$g(b)
CZ296087B6 (en) * 2000-05-11 2006-01-11 Consejo Superior Investigaciones Cientificas Pharmaceutical composition intended for the treatment of a disease in which heterocyclic inhibitors of glycogen synthase kinase GSK-3 are involved
ES2166328B1 (en) * 2000-05-11 2003-09-16 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES
IL153851A0 (en) * 2000-07-27 2003-07-31 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
SI1318997T1 (en) 2000-09-15 2006-12-31 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
AU2001296959A1 (en) * 2000-10-02 2002-04-15 Reddy Us Therapeutics, Inc Methods and compositions for the treatment of inflammatory diseases
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
KR20080014934A (en) * 2000-11-07 2008-02-14 노파르티스 아게 Indolylmaleimide derivatives as protein kinase c inhibitors
EP1345946B1 (en) 2000-12-08 2005-08-10 Ortho-McNeil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
BR0116411A (en) 2000-12-21 2003-11-11 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
WO2002088078A2 (en) 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES
WO2003024447A1 (en) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
AU2002364536B2 (en) 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
EP1465610B1 (en) * 2002-01-10 2008-12-31 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
KR20040084896A (en) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Heteroaryl compounds useful as inhibitors of gsk-3
JP2005525362A (en) * 2002-03-01 2005-08-25 カイロン コーポレイション Methods and compositions for the treatment of ischemia
AU2003215325B8 (en) 2002-03-05 2008-10-09 Eli Lilly And Company Purine derivatives as kinase inhibitors
AU2003217596A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors
WO2003095452A1 (en) 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20050267133A1 (en) * 2002-07-23 2005-12-01 Brown Matthew L Pyrazolopyrimidines as kinase inhibitors
BR0313176A (en) 2002-08-02 2005-06-14 Vertex Pharma Pyrazole compositions useful as gsk-3 inhibitors
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7488826B2 (en) 2003-03-27 2009-02-10 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
JPWO2004091663A1 (en) * 2003-04-18 2006-07-06 協和醗酵工業株式会社 Nerve regeneration drug
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
US8048454B2 (en) * 2004-03-09 2011-11-01 Michael Martin Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3)
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
CA2566392A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
WO2006061212A1 (en) 2004-12-08 2006-06-15 Johannes Gutenberg-Universität Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
CA2595004A1 (en) * 2005-01-18 2006-07-27 Kyoto University Remedy for nerve cell regeneration
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101316843B (en) 2005-11-03 2013-01-02 顶点医药品公司 Aminopyrimidines useful as kinase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PL2383271T3 (en) 2006-03-13 2013-12-31 Kyorin Seiyaku Kk Aminoquinolones as GSK-3 Inhibitors
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
MX2009008253A (en) 2007-01-31 2009-10-12 Vertex Pharma Kinase inhibitors.
NZ579485A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
AU2008282156B2 (en) 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
AU2008299903B2 (en) 2007-09-11 2013-08-29 Kyorin Pharmaceutical Co., Ltd Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN101855229A (en) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 Spirocyclic aminoquinolones as GSK-3 inhibitors
US20110184046A1 (en) * 2008-07-11 2011-07-28 Dinah Wen-Yee Sah Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
GB201111427D0 (en) * 2011-07-05 2011-08-17 Amakem Nv Novel bisindolylmaleimides, pan-pkc inhibitors
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (en) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituted pyrroles, their use for preparing medicaments and medicaments based thereon
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
KR100304210B1 (en) * 1995-11-20 2001-11-05 피터 지. 스트링거 Protein Kinase C Inhibitor
AU2819397A (en) * 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)

Also Published As

Publication number Publication date
WO2000038675A1 (en) 2000-07-06
EP1140070A1 (en) 2001-10-10
AU1877700A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
GB9828640D0 (en) Novel method and compounds
EP1102535A4 (en) Compounds and methods
GB9809414D0 (en) Method
GB9809776D0 (en) Method
GB9814055D0 (en) Method
GB9819764D0 (en) Method
GB9810722D0 (en) Method
GB9819769D0 (en) Method
GB9817266D0 (en) Method
GB9802475D0 (en) Method
GB9820185D0 (en) Method
GB9707251D0 (en) Novel method and compounds
GB9809782D0 (en) Method
GB9809780D0 (en) Method
GB9821974D0 (en) Novel method and compounds
GB9827521D0 (en) Novel method and compounds
GB9814199D0 (en) Novel method
GB9804355D0 (en) Method
GB9806710D0 (en) Novel method
GB9828087D0 (en) Novel method
GB9815877D0 (en) Novel method
GB9815876D0 (en) Novel method
GB9815875D0 (en) Novel method
GB9815872D0 (en) Novel method
GB9814157D0 (en) Novel method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)